BRPI0416755A - uso de inibidores de catepsina k para o tratamento de doenças de perda óssea severa - Google Patents

uso de inibidores de catepsina k para o tratamento de doenças de perda óssea severa

Info

Publication number
BRPI0416755A
BRPI0416755A BRPI0416755-4A BRPI0416755A BRPI0416755A BR PI0416755 A BRPI0416755 A BR PI0416755A BR PI0416755 A BRPI0416755 A BR PI0416755A BR PI0416755 A BRPI0416755 A BR PI0416755A
Authority
BR
Brazil
Prior art keywords
inhibitors
cathepsin
treatment
bone loss
loss diseases
Prior art date
Application number
BRPI0416755-4A
Other languages
English (en)
Inventor
Martin Missbach
Rainer Gamse
Ulrich Trechsel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0416755A publication Critical patent/BRPI0416755A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE INIBIDORES DE CATEPSINA K PARA O TRATAMENTO DE DOENçAS DE PERDA óSSEA SEVERA". Esta invenção refere-se em geral a inibidores de catepsina K e seu uso em crescimento ósseo. Especificamente, a invenção refere-se ao uso de inibidores de catepsina K para estimular nova formação óssea em pacientes que necessitam da mesma.
BRPI0416755-4A 2003-11-19 2004-04-19 uso de inibidores de catepsina k para o tratamento de doenças de perda óssea severa BRPI0416755A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03026430 2003-11-19
PCT/EP2004/004155 WO2005049028A1 (en) 2003-11-19 2004-04-19 Use of cathepsin k inhibitors in severe bone loss diseases

Publications (1)

Publication Number Publication Date
BRPI0416755A true BRPI0416755A (pt) 2007-02-27

Family

ID=34610055

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416755-4A BRPI0416755A (pt) 2003-11-19 2004-04-19 uso de inibidores de catepsina k para o tratamento de doenças de perda óssea severa

Country Status (16)

Country Link
US (1) US20070135448A1 (pt)
EP (1) EP1686995A1 (pt)
JP (1) JP2007511548A (pt)
KR (1) KR20060107792A (pt)
CN (1) CN1882343A (pt)
AU (1) AU2004290874A1 (pt)
BR (1) BRPI0416755A (pt)
CA (1) CA2545723A1 (pt)
IL (1) IL175436A0 (pt)
IS (1) IS8498A (pt)
MA (1) MA28174A1 (pt)
MX (1) MXPA06005635A (pt)
NO (1) NO20062870L (pt)
TN (1) TNSN06147A1 (pt)
TW (1) TW200526198A (pt)
WO (1) WO2005049028A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427380D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
US20080076723A1 (en) * 2006-09-27 2008-03-27 Sylvan Pharmaceuticals Pty Ltd. Inhibition of cathepsin K activity and the treatment and prevention of disease
WO2008104271A2 (en) 2007-02-28 2008-09-04 Sanofi-Aventis Imaging probes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
SK6572000A3 (en) * 1997-11-05 2000-10-09 Novartis Ag Dipeptide nitriles, process for the preparation thereof, their use as medicaments and pharmaceutical composition comprising them
JP3892187B2 (ja) * 1998-11-12 2007-03-14 生化学工業株式会社 環状アミド誘導体
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
CA2532948A1 (en) * 2003-07-21 2005-02-17 Novartis Ag Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss

Also Published As

Publication number Publication date
IS8498A (is) 2006-06-06
CA2545723A1 (en) 2005-06-02
TW200526198A (en) 2005-08-16
MA28174A1 (fr) 2006-09-01
NO20062870L (no) 2006-08-18
KR20060107792A (ko) 2006-10-16
AU2004290874A1 (en) 2005-06-02
IL175436A0 (en) 2008-04-13
MXPA06005635A (es) 2006-08-17
JP2007511548A (ja) 2007-05-10
CN1882343A (zh) 2006-12-20
TNSN06147A1 (en) 2007-11-15
EP1686995A1 (en) 2006-08-09
WO2005049028A1 (en) 2005-06-02
US20070135448A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
BR0308663A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
EE05419B1 (et) Asendatud oksasolidinoonid kombineeritud raviks
UY28314A1 (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
MEP42808A (en) Use of flibanserin in the treatment of sexual disorders
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
BR0210075A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou distúrbios da debilitação intelectual e de fadiga de vÈo, cessamento de fumar, dependência de nicotina, dores, e para a colite ulcerativa
ECSP066608A (es) Suspensiones acuosas de ciclesonide para nebulización
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
AU2003250190A1 (en) Combination of an aromatase inhibitor with a bisphosphonate
GB0020504D0 (en) Therapeutic method
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
BRPI0514390A (pt) enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
BR0312929A (pt) Uso de um composto, e, métodos de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo, e da degeneração macular relacionada com a idade de um corpo de animal vivo
BRPI0416755A (pt) uso de inibidores de catepsina k para o tratamento de doenças de perda óssea severa
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
ECSP034632A (es) Uso de compuestos del 6-dimetilaminometil-1-fenil-ciclohexaco sustituido en la terapia de la incontinencia urinaria
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
DE60226126D1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
RU2001101202A (ru) Способ хирургического лечения больных с артериальными окклюзиями
ATE464051T1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.